Understanding immunogenicity is a key challenge in the development of therapeutics with many biologics inducing undesirable immune responses directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and occasionally life threatening autoimmunity. This conference explores the latest updates on the prediction and reduction of immunogenicity, clinical results and interpetations and optimising bioassays.
Led by selected case studies from leading drug developement teams, bioanalytical experts, and academics we aim to provide the insights and sharing necessary to deliver safe, efficacious large molecule drugs to improve the lives of patients.
Electronic Access - Single User Fulfilled By Publisher
CD-ROM Mail Delivery
Electronic Access - Global site License Fulfilled By Publisher